| 000 | 01048 a2200277 4500 | ||
|---|---|---|---|
| 005 | 20250512020124.0 | ||
| 264 | 0 | _c19891019 | |
| 008 | 198910s 0 0 eng d | ||
| 022 | _a0031-6970 | ||
| 024 | 7 |
_a10.1007/BF00637733 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBechtel, P R | |
| 245 | 0 | 0 |
_aCriteria for the choice and definition of healthy volunteers and or patients for phase I and phase II studies in drug development. Commentary on an action for cooperative research. _h[electronic resource] |
| 260 |
_bEuropean journal of clinical pharmacology _c1989 |
||
| 300 |
_a549-50 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aDrug Evaluation |
| 650 | 0 | 4 | _aEurope |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInternational Cooperation |
| 650 | 0 | 4 | _aPharmacogenetics |
| 650 | 0 | 4 | _aPolymorphism, Genetic |
| 700 | 1 | _aAlvan, G | |
| 773 | 0 |
_tEuropean journal of clinical pharmacology _gvol. 36 _gno. 6 _gp. 549-50 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/BF00637733 _zAvailable from publisher's website |
| 999 |
_c2782681 _d2782681 |
||